About Pantrone

Pantrone Consulting Co. Ltd. was established in 2019 and is a Contract Research Organization (CRO) specializing in cell therapy clinical trials. Pantrone is composed of a team of top-notch doctoral and master’s graduates from domestic and international universities.

Dr. Pan, the founder, graduated from the Department of Microbiology at National Taiwan University’s College of Medicine and EMBA from National Cheng-Chi University, and has over 15 years of experience in the biotechnology industry. His expertise includes the development of cell therapy products and small molecule drugs, as well as extensive experience in clinical trials, startups, and biotech investments. Our mission is to assist Taiwanese biotech companies in developing new drugs and accelerating their entry into clinical trials to save more lives.

Pantrone has successfully obtained multiple approvals for Investigational New Drug (IND) applications from the U.S. Food and Drug Administration (FDA), including the first Taiwan-based allogeneic chimeric antigen receptor T-cell (Car-T) therapy, and the first Taiwan-based exosome to receive IND approval in the United States. We provide the most professional services for clinical trials of cell products, and we believe Pantrone is your best choice for developing cell products.